keyword
MENU ▼
Read by QxMD icon Read
search

Antipsychotic induced weight gain

keyword
https://www.readbyqxmd.com/read/28624847/the-microbiome-gut-brain-axis-implications-for-schizophrenia-and-antipsychotic-induced-weight-gain
#1
REVIEW
S Kanji, T M Fonseka, V S Marshe, V Sriretnakumar, M K Hahn, D J Müller
With the emergence of knowledge implicating the human gut microbiome in the development and regulation of several physiological systems, evidence has accumulated to suggest a role for the gut microbiome in psychiatric conditions and drug response. A complex relationship between the enteric nervous system, the gut microbiota and the central nervous system has been described which allows for the microbiota to influence and respond to a variety of behaviors and psychiatric conditions. Additionally, the use of pharmaceuticals may interact with and alter the microbiota to potentially contribute to adverse effects of the drug...
June 17, 2017: European Archives of Psychiatry and Clinical Neuroscience
https://www.readbyqxmd.com/read/28601891/effect-of-liraglutide-treatment-on-prediabetes-and-overweight-or-obesity-in-clozapine-or-olanzapine-treated-patients-with-schizophrenia-spectrum-disorder-a-randomized-clinical-trial
#2
Julie R Larsen, Louise Vedtofte, Mathilde S L Jakobsen, Hans R Jespersen, Michelle I Jakobsen, Camilla K Svensson, Kamuran Koyuncu, Ole Schjerning, Peter S Oturai, Andreas Kjaer, Jimmi Nielsen, Jens J Holst, Claus T Ekstrøm, Christoph U Correll, Tina Vilsbøll, Anders Fink-Jensen
Importance: Compared with the general population, patients with schizophrenia have a 2- to 3-fold higher mortality rate primarily caused by cardiovascular disease. Previous interventions designed to counteract antipsychotic-induced weight gain and cardiometabolic disturbances reported limited effects. Objectives: To determine the effects of the glucagon-like peptide-1 receptor agonist liraglutide added to clozapine or olanzapine treatment of schizophrenia spectrum disorders...
June 10, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28595931/aripiprazole-induced-adverse-metabolic-alterations-in-polyi-c-neurodevelopmental-model-of-schizophrenia-in-rats
#3
Katerina Horska, Jana Ruda-Kucerova, Eva Drazanova, Michal Karpisek, Regina Demlova, Tomas Kasparek, Hana Kotolova
Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis...
June 13, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28586744/protective-effects-of-green-tea-on-olanzapine-induced-metabolic-syndrome-in-rats
#4
Bibi Marjan Razavi, Fariba Lookian, Hossein Hosseinzadeh
Atypical antipsychotics particularly olanzapine are associated with obesity and serious metabolic disturbances. As green tea (Camellia sinensis) is generally associated with beneficial effects on obesity and other metabolic disturbances, this study was undertaken to evaluate the effect of green tea aqueous extract (GTAE) on olanzapine induced weight gain and metabolic abnormalities in rats. Male Wistar rats were divided into eight groups: control, olanzapine (5mg/kg/day, IP.), GTAE (25, 50 and 100mg/kg/day, IP...
June 3, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28584269/time-dependent-changes-and-potential-mechanisms-of-glucose-lipid-metabolic-disorders-associated-with-chronic-clozapine-or-olanzapine-treatment-in-rats
#5
Xuemei Liu, Zhixiang Wu, Jiamei Lian, Chang-Hua Hu, Xu-Feng Huang, Chao Deng
Chronic treatment with second-generation antipsychotic drugs (SGAs) has been associated with an increased risk of metabolic syndrome. To evaluate the longitudinal changes in glucose-lipid homeostasis after SGA use, we studied the time-dependent effects of olanzapine (OLZ) (3 mg/kg, b.i.d.) or clozapine (CLZ) (20 mg/kg, b.i.d.) treatment on metabolic profiles for 9 weeks in rats. Although only OLZ significantly increased body weight in rats, both OLZ and CLZ elevated blood lipid levels. Chronic OLZ treatment induced significant weight gain leading to a higher fasting insulin level and impaired glucose tolerance, whereas CLZ lowered fasting insulin levels and impaired glucose tolerance independent of weight gain...
June 5, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28579786/topiramate-add-on-treatment-associated-with-normalization-of-prolactin-levels-in-a-patient-with-schizophrenia
#6
Yinglin Huang, Huan Ma, Yuan Wang, Miao Peng, Gang Zhu
Topiramate has been used increasingly in the management of psychiatric conditions. Clinical trials demonstrated that topiramate augmentation was effective in controlling negative symptoms in schizophrenia. This case report presents a case of a 38-year-old man with schizophrenia who achieved full negative symptom remission upon the adjunctive use of topiramate. However, the remarkable finding of this case is the concomitant decrease in the level of prolactin when topiramate (50 mg/day) was started and the rebound after discontinuation of topiramate...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28560263/dopamine-d2-receptors-and-the-circadian-clock-reciprocally-mediate-antipsychotic-drug-induced-metabolic-disturbances
#7
Zachary Freyberg, Michael J McCarthy
Antipsychotic drugs are widely prescribed medications, used for numerous psychiatric illnesses. However, antipsychotic drugs cause serious metabolic side effects that can lead to substantial weight gain and increased risk for type 2 diabetes. While individual drugs differ, all antipsychotic drugs may cause these important side effects to varying degrees. Given that the single unifying property shared by these medications is blockade of dopamine D2 and D3 receptors, these receptors likely play a role in antipsychotic drug-induced metabolic side effects...
2017: NPJ Schizophrenia
https://www.readbyqxmd.com/read/28540050/effect-of-atypical-antipsychotics-on-body-weight-in-geriatric-psychiatric-inpatients
#8
Eugene Yh Yeung, Soojin Chun, Alan Douglass, Timothy E Lau
BACKGROUND: Studies suggest that antipsychotic-induced weight gain is not a great concern in the elderly population. This study investigated the weight change in elderly patients with various treatment duration and antipsychotics. Part 1 of the study was to determine whether atypical antipsychotics induced weight change in elderly patients. Part 2 was to determine whether certain atypical antipsychotics induced more weight change in elderly patients. METHODS: In Part 1, a retrospective chart review was done on 115 geriatric inpatients...
2017: SAGE Open Medicine
https://www.readbyqxmd.com/read/28531893/association-study-of-serotonin-3-receptor-subunit-gene-variants-in-antipsychotic-induced-weight-gain
#9
Clement C Zai, Arun K Tiwari, Nabilah I Chowdhury, Eva J Brandl, Sajid A Shaikh, Natalie Freeman, Jeffrey A Lieberman, Herbert Y Meltzer, James L Kennedy, Daniel J Müller
BACKGROUND: Schizophrenia (SCZ) is a chronic severe neuropsychiatric disorder, where pharmacological treatment has been hindered by adverse effects, including antipsychotic-induced weight gain (AIWG) and related complications. Genetic studies have been exploring the appetite regulation and energy homeostasis pathways in AIWG with some promising leads. The serotonin system has been shown to participate in these pathways. METHODS: In the current study, we examined single nucleotide polymorphisms across the serotonin receptor genes HTR3A and HTR3B...
2016: Neuropsychobiology
https://www.readbyqxmd.com/read/28507773/rapid-onset-clozapine-induced-loss-of-glycaemic-control-case-report
#10
Alejandro Porras-Segovia, Amir Krivoy, Mark Horowitz, George Thomas, Mark Bolstridge, Dragos Ion, Sukhwinder S Shergill
Clozapine has proved to be an effective antipsychotic for the treatment of refractory schizophrenia - characterised by the persistence of symptoms despite optimal treatment trials with at least two different antipsychotics at adequate dose and duration - but its use is hampered by adverse effects. The development of clozapine-induced diabetes is commonly considered to arise as part of a metabolic syndrome, associated with weight gain, and thus evolves slowly. We present the case of an individual with refractory schizophrenia and metformin-controlled diabetes who developed rapid-onset insulin-dependent hyperglycaemia immediately after starting clozapine...
May 2017: BJPsych Open
https://www.readbyqxmd.com/read/28463344/minimizing-weight-gain-for-patients-taking-antipsychotic-medications-the-potential-role-for-early-use-of-metformin
#11
Victoria Hendrick, Robert Dasher, Michael Gitlin, Mehrban Parsi
BACKGROUND: Patients taking antipsychotic medications are at high risk for weight gain, which in turn leads to poor health outcomes, nonadherence with treatment, and low self-esteem. METHODS: We reviewed published studies of pharmacologic interventions aimed at minimizing antipsychotic-induced weight gain. Treatments initiated prior to onset of weight gain were compared with those that started once weight gain already had occurred. RESULTS: Although data are limited, adjunctive medications for weight management appear to be more effective when initiated at or near the time when patients are first exposed to antipsychotic medications...
May 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/28453334/different-immune-signature-in-youths-experiencing-antipsychotic-induced-weight-gain-compared-to-untreated-obese-patients
#12
Simone Pisano, Gennaro Catone, Giangennaro Coppola, Marco Carotenuto, Raffaella Iuliano, Claudia Tiano, Anna Rita Montesanto, Vittoria D'Esposito, Emanuele Del Giudice Miraglia, Pietro Formisano, Carmela Bravaccio
OBJECTIVES: To assess cytokine and chemokine levels in youth experiencing antipsychotic-induced weight gain (AIWG) compared to obese patients, hypothesizing a different "immune signature" between the two kinds of obesity. METHODS: We compared a group of youth experiencing AIWG (N 19, mean age 159 months, mean body mass index [BMI] z-score 1.81) and an age-, gender-, and BMI-matched group of untreated obese patients (N 19, mean age 147 months, mean BMI z-score 2) for a wide range of cytokines and chemokines by using a multiplex ELISA test...
April 28, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28447303/brief-report-metformin-for-antipsychotic-induced-weight-gain-in-youth-with-autism-spectrum-disorder
#13
Logan K Wink, Ryan Adams, Ernest V Pedapati, Kelli C Dominick, Emma Fox, Catherine Buck, Craig A Erickson
Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD...
April 26, 2017: Journal of Autism and Developmental Disorders
https://www.readbyqxmd.com/read/28408348/design-and-in-vivo-evaluation-of-solid-lipid-nanoparticulate-systems-of-olanzapine-for-acute-phase-schizophrenia-treatment-investigations-on-antipsychotic-potential-and-adverse-effects
#14
Emil Joseph, Satish Reddi, Vibhu Rinwa, Garima Balwani, Ranendra Saha
The present paper discusses the design, characterization and in vivo evaluation of glyceryl monostearate nanoparticles of Olanzapine, an atypical antipsychotic drug for acute schizophrenia treatment, during which hospitalization is mandatory and adverse effects are at its peak. The solid lipid nanoparticulate system was obtained by emulsification-ultra sonication technique wherein three factors such as solid lipid content, concentration of surfactant and drug: solid lipid ratio were selected at three different levels in order to study their influence on significant characteristic responses such as particle size, encapsulation efficiency and drug content...
April 11, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28400260/prevention-of-the-adverse-effects-of-olanzapine-on-lipid-metabolism-with-the-antiepileptic-zonisamide
#15
Aneta Stefanidis, Matthew J Watt, Michael A Cowley, Brian J Oldfield
BACKGROUND: Atypical antipsychotic drugs, particularly olanzapine, represent a mainstay in the treatment of psychoses; however, their use is commonly associated with weight gain and diabetes. The aim of this study was to determine whether combined administration of olanzapine and zonisamide can be used to prevent olanzapine-induced metabolic disturbances. METHODS AND RESULTS: These experiments involved female Sprague Dawley rats (n = 6-8/group) that were administered olanzapine, either acutely (6 mg/kg, s...
April 8, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28377074/metabolic-side-effects-induced-by-olanzapine-treatment-are-neutralized-by-cb1-receptor-antagonist-compounds-co-administration-in-female-rats
#16
P Lazzari, V Serra, S Marcello, M Pira, A Mastinu
Weight gain is an important side effect of most atypical antipsychotic drugs such as olanzapine. Moreover, although many animal models with metabolic side effects have been well defined, the interaction with other pathways has to be considered. The endocannabinoid system and the CB1 receptor (CB1R) are among the most promising central and peripheral targets involved in weight and energy balance. In this study we developed a rat model based 15-days treatment with olanzapine that shows weight gain and an alteration of the blood parameters involved in the regulation of energy balance and glucose metabolism...
April 1, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28347259/metformin-for-antipsychotic-induced-weight-gain-statistical-curiosities
#17
Ekta Franscina Pinto, Biju George, Sagar Karia, Chittaranjan Andrade
No abstract text is available yet for this article.
April 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28347258/depot-risperidone-induced-adverse-metabolic-alterations-in-female-rats
#18
Katerina Horska, Jana Ruda-Kucerova, Michal Karpisek, Pavel Suchy, Radka Opatrilova, Hana Kotolova
Atypical antipsychotics are associated with adverse metabolic effects including weight gain, increased adiposity, dyslipidaemia, alterations in glucose metabolism and insulin resistance. Increasing evidence suggests that metabolic dysregulation precedes weight gain development. The aim of this study was to evaluate alterations in adipokines, hormones and basic serum biochemical parameters induced by chronic treatment with depot risperidone at two doses (20 and 40 mg/kg) in female Sprague-Dawley rats. Dose-dependent metabolic alterations induced by risperidone after 6 weeks of treatment were revealed...
April 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28327672/tox-and-adipoq-gene-polymorphisms-are-associated-with-antipsychotic-induced-weight-gain-in-han-chinese
#19
Shen Li, Chengai Xu, Yuan Tian, Xueshi Wang, Rui Jiang, Miaomiao Zhang, Lili Wang, Guifu Yang, Ying Gao, Chenyu Song, Yukun He, Ying Zhang, Jie Li, Wei-Dong Li
To find the genetic markers related to the antipsychotic-induced weight gain (AIWG), we analyzed associations among candidate gene single-nucleotide polymorphisms (SNPs) and quantitative traits of weight changes and lipid profiles in a Chinese Han population. A total of 339 schizophrenic patients, including 86 first-episode patients (FEPs), meeting the entry criteria were collected. All patients received atypical antipsychotic drug monotherapy and hospitalization and were followed for 12 weeks. Forty-three SNPs in 23 candidate genes were calculated for quantitative genetic association with AIWG, performed by PLINK...
March 22, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28300948/superwellness-program-a-cognitive-behavioral-therapy-based-group-intervention-to-reduce-weight-gain-in-patients-treated-with-antipsychotic-drugs
#20
Laura R Magni, Clarissa Ferrari, Giuseppe Rossi, Elena Staffieri, Aldo Uberti, Dario Lamonaca, Ileana Boggian, Silvia Merlin, Giuseppe Primerano, Alessandra Mombrini, Roberto Poli, Francesco M Saviotti, Maria T Caldera, Luciana Zanotti, Roberta Rossi
Objective: To assess the effectiveness of a cognitive-behavioral therapy-based intervention (Superwellness Program) on weight gain compared with a treatment-as-usual (TAU) approach in patients treated with antipsychotics, and to evaluate the relationship between body mass index (BMI) variation and clinical variables. Method: Eighty-five patients treated with antipsychotics were allocated across two groups, experimental (n=59) and control (n=26). The Superwellness Program (experimental group) consisted of 32 twice-weekly 1-hour sessions, conducted by a psychologist and a nutritionist/nurse, concurrently with moderate food intake and moderate physical activity plans...
March 13, 2017: Revista Brasileira de Psiquiatria
keyword
keyword
99026
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"